End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
41.36 CNY | -1.45% |
|
-1.76% | -8.56% |
06-18 | Hengrui Pharmaceuticals, Subsidiary Get Regulatory Nod to Test Two Drugs | MT |
06-05 | Hengrui Pharma Units Get China Nod for Clinical Trial of Tumor Drug | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.56% | 36.24B | |
+52.93% | 803B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.58% | 243B | |
+1.84% | 228B | |
+10.16% | 217B | |
+6.24% | 164B | |
-4.79% | 155B |
- Stock Market
- Equities
- 600276 Stock
- News Jiangsu Hengrui Medicine Co., Ltd.
- Hengrui Pharmaceuticals to Resubmit Marketing Application for Liver Cancer Drug Combination to US FDA